ATRA (Atara Biotherapeutics) Tax Provision: $-0.03 Mil (TTM As of Mar. 2026)


ATRA Atara Biotherapeutics Inc ATRA
31 GF Score
Price $9.72
GF Value $1.55
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Atara Biotherapeutics Tax Provision?

Atara Biotherapeutics ATRA -2.59% 31 Tax Provision is $-0.03 Mil as of Mar. 2026. GuruFocus rates ATRA with a GF Score™ of 31/100 and a GF Value™ of $1.55 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Atara Biotherapeutics's tax provision for the three months ended in Mar. 2026 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.03 Mil.

Atara Biotherapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics Tax Provision Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.01 -0.02 0.01 -0.03

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.03 0.00 0.00
ATRA
31GF Score
Atara Biotherapeutics Inc ATRA
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $-0.03 Mil mean?
Atara Biotherapeutics (ATRA) has a Tax Provision of $-0.03 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' Tax Provision too high?
Atara Biotherapeutics' current Tax Provision is $-0.03 Mil. Overall, Atara Biotherapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' Tax Provision compare to ANIX and BMEA?
Atara Biotherapeutics' Tax Provision of $-0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current Tax Provision is $-0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Atara Biotherapeutics (ATRA) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.55, compared to a current price of $9.72 — trading 527.1% above its estimated fair value. The current Tax Provision is $-0.03 Mil. Atara Biotherapeutics' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Atara Biotherapeutics (ATRA), the current Tax Provision is $-0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (ATRA) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of $9.72 is trading 527.1% above its estimated GF Value™ of $1.55. GuruFocus considers Atara Biotherapeutics to be Significantly Overvalued.

Key valuation signals for ATRA:

  • Tax Provision: $-0.03 Mil
  • GF Value™: $1.55 vs. price of $9.72 (527.1% above fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the ATRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges 0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for ATRA

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.72
Price
$1.55
GF Value